Document:

<PAGE>

                                                                Exhibit 10.27

                              EMPLOYMENT AGREEMENT

         This Employment Agreement (herein referred to as "AGREEMENT") is made
and entered into as of this 29th day of April 2001, by and among Aurora
Biosciences Corporation (the "COMPANY"), and Harry Stylli ("EXECUTIVE").

         WHEREAS, Executive's expertise and his reputation in the Company's
industry and the services to be performed by Executive under the terms of this
Agreement are of a special, unique, unusual, extraordinary, and intellectual
character, which gives the services of Executive a peculiar value;

         WHEREAS, in connection with the transaction contemplated in that
certain Agreement and Plan of Merger ("Merger Agreement") dated as of April
29th, 2001, by and among Vertex Pharmaceuticals Incorporated, a Massachusetts
corporation ("Vertex"), Ahab Acquisition Sub, Inc., a Delaware corporation and a
wholly owned subsidiary of Vertex, and the Company, Vertex has requested the
continued employment by the Company of Executive after the Closing Date (as such
term is defined in the Merger Agreement);

         WHEREAS,  Executive wishes to continue to be employed by the Company
upon the terms and conditions herein set forth;

         NOW, THEREFORE, in consideration of the premises and of the mutual
covenants contained herein, the parties hereto agree as follows:

         1. EMPLOYMENT. The Company hereby employs  Executive and Executive
hereby accepts such  employment upon the terms and conditions herein set forth.

         2. TERM OF AGREEMENT/PRIOR AGREEMENTS. Except as otherwise provided in
the third sentence of this Section 2, this Agreement shall become effective as
of the Closing Date (the "Commencement Date") and shall continue until
terminated as hereinafter provided. As of the Commencement Date, all other
agreements between the Company and Executive relating to his/her employment,
except as expressly provided in Section 4(e) below, hereby are superceded and
replaced by this Agreement and all other such agreements, whether oral or
written, are of no further force or effect. Without limiting the foregoing,
Executive hereby agrees, effective as of the date this Agreement is signed, to
the rescission of the Change in Control Incentive Plan dated March 26, 2001,
rescinded effective as of the date this Agreement is signed, and acknowledges
that he has no rights pursuant to such plan. Notwithstanding any other provision
of this Agreement, however, nothing in this Agreement shall in any way affect
Executive's rights to stock options granted pursuant to the Company's 1996 Stock
Plan, as amended (the "Aurora Stock Plan"); provided, however, that Executive
specifically acknowledges and agrees that (i) Executive's employment pursuant to
this agreement shall not be deemed to be a "Constructive Termination" for
purposes of Section 2(i) of the Aurora Stock Plan, and (ii) notwithstanding any
provision of such plan to the contrary, nothing in this Agreement shall be
deemed to extend or enlarge Executive's rights under such plan, including,

<PAGE>

without limitation, nothing shall be deemed to extend the thirteen month
post-closing period referred to in Section 13 of such plan.

         3.  DUTIES OF EXECUTIVE.

             (a) RESPONSIBILITY/REPORTING. Executive shall be employed as
the Company's President. Executive's duties shall be such executive, managerial,
administrative, and professional duties as are commensurate with his position
and as shall be reasonably assigned by the Vertex Chief Executive Officer or his
or her designee. Executive initially shall report to Joshua Boger, Chief
Executive Officer of Vertex, and shall work out of the San Diego office of the
Company.

             (b) DEVOTION OF DUTIES. During his employment hereunder,
Executive shall devote his full business time and his best efforts, business
judgment, skill and knowledge to the performance of his duties and
responsibilities hereunder. Executive shall not engage in any other business
activity during the term of this Agreement (the "Term") other than activity
approved in writing by the Board.

         4.  COMPENSATION AND BENEFITS.

             (a) SALARY. Executive's annual base salary shall be two hundred and
fifty thousand dollars ($250,000), which base salary shall be reviewed annually
by the Board. Executive's annual base salary shall be paid in approximately
equal installments consistent with the Company's practices for its Executives.

             (b) BONUSES.

             In consideration of Executive's continued service to the Company
and as an incentive for him to use his best business efforts to promote and
facilitate the integration of Vertex and the Company following consummation of
the Merger, Executive shall be entitled to a retention bonus of two hundred
fifty thousand dollars ($250,000), payable as follows: (i) fifty thousand
dollars ($50,000) shall be payable to Executive on the Commencement Date, (ii)
one hundred thousand dollars ($100,000) shall be payable on January 1, 2002 or
the first business day thereafter, and (iii) one hundred thousand dollars
($100,000) shall be payable on January 1, 2003 or the first business day
thereafter, if, (A) in the case of (ii) above, as of December 31, 2001 the
milestones listed in Exhibit B have been met and (B) unless such amounts are
earlier payable in accordance with Section 6(c) below, Executive remains
employed by the Company on each such date set forth in (ii) and (iii). No
portion of such retention bonus shall be earned until the date on which such
portion is payable either in accordance with this Section 4(b) or, if
applicable, in accordance with Section 6(c). The bonus contemplated in this
paragraph is referred to herein as the "Retention Bonus."

             In addition, Executive shall be entitled to a bonus under the
Company's 2001 Annual Bonus Performance Plan (the "2001 Bonus"), with
performance objectives to be determined mutually by Executive and the
Compensation Committee of Vertex's Board of Directors (the "Vertex Compensation
Committee") on a basis comparable to that used to

                                       2

<PAGE>

determine achievement of performance bonus goals for the year 2000, and subject
to the approval of the Vertex Compensation Committee. Such bonus will be paid by
the Company in accordance with its normal practices and procedures for payment
of bonus amounts.

             In addition, beginning with the year 2002, Executive shall be
eligible to participate in Vertex's bonus plans applicable generally to other
senior executives of Vertex.

             Executive's base salary, bonuses and all other cash compensation
shall be subject to such social security, unemployment insurance, withholding
taxes and other payroll deductions as are required to be made by law.

             (c) FRINGE BENEFITS. Executive shall be entitled to benefits which
in the aggregate are at least comparable to those which he currently receives
from the Company.

             (d) VERTEX STOCK OPTIONS. Promptly following the closing of the
Merger, Executive shall be considered for the grant of an option to purchase
shares of Vertex's common stock pursuant to Vertex's 1996 Stock and Option Plan,
as amended, at a level commensurate with similarly situated executive employees
of Vertex. Vertex shall cause its Compensation Committee of its Board of
Directors to meet promptly following the closing of the Merger to consider such
grant.

             (e) EXISTING STOCK OPTIONS. Except as modified by the last sentence
of Section 2 above, Executive's existing stock options granted by the Company
prior to the Commencement Date shall remain subject to the terms of the Aurora
Stock Plan, as amended.

         5. NON-COMPETITION BY EXECUTIVE. On the Commencement Date, Executive
shall execute the Non-Disclosure, Non-Competition, and Inventions Agreement, a
copy of which is attached hereto as Exhibit A (the "Non-Compete Agreement"). The
obligations of Executive under the Non-Compete Agreement shall survive any
breach or termination of this Agreement.

                                       3

<PAGE>

         6. TERMINATION.

         (a) Executive's employment with the Company will be "at-will", meaning
that Executive may terminate his/her employment with the Company at any time and
for any reason whatsoever, with or without advance notice and likewise, the
Company, may terminate Executive's employment at any time and for any reason
whatsoever, with or without advance notice. This at-will arrangement may not be
changed except by a writing signed by Executive and a duly authorized officer of
the Company.

         (b) Upon termination of Executive's employment with the Company at any
time, Executive will be paid his/her then current accrued base salary to and
including the date of termination, any unpaid portion of the 2001 Bonus
(provided that if such termination occurs during the calendar year 2001, the
2001 Bonus shall be reduced to an amount determined by multiplying the full 2001
Bonus by a fraction, the numerator of which shall be the number of days
occurring during such year prior to and including the day of termination and the
denominator of which shall be 365), any accrued vacation pay, any reimbursement
of expenses for which Executive has not been previously reimbursed and other
benefits through the date of termination and all compensation previously
deferred by Executive, if any (together with accrued interest and earnings
thereon) (the foregoing are referred to herein as "Accrued Obligations"). Except
as provided in Section 6(c), thereafter no other payments shall be payable under
this Agreement to Executive.

         (c) Notwithstanding the foregoing, if Executive's employment is
terminated without Cause by the Company or with Good Reason by the Executive
within the eighteen (18) month period following the Closing (as defined in the
Merger Agreement), in exchange for a general release of all claims the Executive
shall receive the Accrued Obligations and the following:

         (1)  the Company shall pay Executive, in cash within ten (10) days
              following such termination or resignation, a lump sum equal to
              twelve months' of Executive's base salary in effect immediately
              prior to such termination and an amount equal to one hundred
              percent (100%) of the annual bonus most recently received by
              Executive (exclusive of the Retention Bonus provided for in the
              first paragraph of Section 4(b) above); and

         (2)  the Company shall pay Executive, in cash within ten (10) days
              following such termination or resignation, a lump sum equal to any
              unpaid amount of the Retention Bonus provided for in the first
              paragraph of Section 4(b); and

         (3)  if COBRA coverage is elected by Executive, the Company shall pay
              the cost of COBRA continuation premiums to continue medical and
              dental insurance coverage for Executive (and [his][her] qualified
              beneficiaries) until the earlier of one (1) year following
              termination of Executive's employment or the date on which
              Executive becomes eligible for comparable coverage under another
              employer's group medical and dental insurance plan.

         If Executive's employment is terminated without Cause by the Company or
with Good Reason by the Executive more than eighteen (18) months after the
Closing (as defined in the

                                       4

<PAGE>

Merger Agreement), then in exchange for a general release of all claims the
Executive shall receive the Accrued Obligations and a lump sum equal to six
months' of Executive's base salary in effect immediately prior to such
termination.

         Executive shall not be required to mitigate the amount of the severance
payment or any other benefit provided under this Agreement by seeking other
employment or otherwise, nor shall the amount of any payment or benefit provided
for in this Agreement be reduced by any compensation earned by Executive as the
result of other employment by another employer, by retirement benefits, by
offset against any amount claimed to be owed by Executive to the Company or
otherwise, except as specifically provided for in Section 6(c)(3).

          Any severance payable under this Section 6(c) shall be payable only
after Executive has executed a general release of all claims against the Company
and any applicable revocation period has expired without revocation.

         "Cause" shall be limited to the occurrence of any of the following
events: (i) Executive personally engaging in illegal conduct which causes
material harm to the reputation of the Company, (ii) Executive being convicted
or found liable for a felony, misdemeanor or gross misconduct relating to an act
of dishonesty or fraud against, or a material misappropriation of property
belonging to the Company, (iii) Executive's refusal to substantially perform
Executive's material duties under this Agreement as set forth in a specific
resolution by the Board of Directors of the Company, or (iv) Executive's
incurable breach of any material element of the Non-Compete Agreement.

         "Good Reason" shall mean (i) a reduction in Executive's base salary
from that specified in the first sentence of Section 4(a) of this Agreement or
any material reduction in benefits; (ii) the relocation of Executive's full-time
office to a location other than in San Diego County; (iii) a material breach by
the Company of any of the provisions of this Agreement or (iv) a substantial
reduction in Executive's duties inconsistent with Executive's duties under this
Agreement.

         (d) Upon the termination of his/her employment hereunder for any reason
whatsoever, Executive shall promptly deliver to the Company all property of the
company and all material documents, statistics, account records, programs and
other similar tangible items which may be in his possession or under his control
and which relate in a material way to the business or affairs of the Company or
of any affiliated company and no copies of any such documents or any part
thereof shall be retained by him. It is specifically understood and agreed that
this provision does not apply to any property granted or given to Executive
under this or any other agreement he may have with the Company.

         7. MISREPRESENTATION; NON-DISPARAGEMENT.

         (a) Executive shall not knowingly at any time make any untrue or
disparaging statement in relation to the Company, and in particular shall not
after the termination of his employment hereunder wrongfully represent himself
as being employed by or connected with the Company.

                                       5

<PAGE>

         (b) The officers, directors and senior executives of the Company shall
not knowingly at any time make any untrue or disparaging statement in relation
to the Executive, nor shall they permit the Company through any authorized
communication (irrespective of the media) to make any untrue or disparaging
statement in relation to the Executive, provided, however, that nothing herein
shall prohibit statements by any such persons among or between themselves with
respect to your performance of your duties to the Company or its affiliates.

         8. REIMBURSEMENT OF EXPENSES. The Company shall reimburse Executive for
all ordinary and necessary out-of-pocket expenses reasonably incurred by
Executive on behalf of the business of the Company. Executive agrees to keep
such records and logs as may be required by the relevant taxing authorities for
the substantiation of each such business expense as a deduction on the Company's
income tax returns.

         9. TAX CONSEQUENCES. If any payment or benefit you would receive
pursuant to this Agreement or otherwise in connection with the Merger
(hereinafter, a "Payment") would (i) constitute a "parachute payment" within the
meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the
"Code"), and (ii) but for this sentence, be subject to the excise tax imposed by
Section 4999 of the Code (the "Excise Tax"), then such Payment shall be reduced
to the Reduced Amount. The "Reduced Amount" shall be either (x) the largest
portion of the Payment that would result in no portion of the Payment being
subject to the Excise Tax or (y) the largest portion, up to and including the
total, of the Payment, whichever amount, after taking into account all
applicable federal, state and local employment taxes, income taxes, and the
Excise Tax (all computed at the highest applicable marginal rate), results in
your receipt, on an after-tax basis, of the greater amount of the Payment. If a
reduction in payments or benefits constituting "parachute payments" is necessary
so that the Payment equals the Reduced Amount, reduction shall occur in the
order you elect. In the event that acceleration of vesting of stock award
compensation is to be reduced, such acceleration of vesting shall be cancelled
in the order you elect.

         10. NOTICES. Any notices to be given hereunder by either party to the
other may be effectuated either by personal delivery in writing or by mail,
postage prepaid, with return receipt requested. Notices shall be addressed to
the parties as follows:

         If to the Company:  Aurora Biosciences Corporation
                             11010 Torreyana Road
                             San Diego, CA 92121

           with a copy to:   Vertex Pharmaceuticals Incorporated
                             130 Waverly Street
                             Cambridge, MA 02139

           with a copy to:   Robert M. Gault, Esq.
                             Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
                             One Financial Center
                             Boston, MA  02111

                                       6

<PAGE>

         If to Executive:    Harry Stylli
                             Address on file at the Company

or to such other addresses as either the Company or Executive may designate by
written notice to each other. Notices delivered personally shall be deemed duly
given on the date of actual receipt; mailed notices shall be deemed duly given
as of the fifth day after the date so mailed. Notices hereunder may be delivered
by electronic facsimile transmission (fax) if confirmation by sender is made
within three business days by mail or personal delivery.

         11. WAIVER OF BREACH. The waiver by any party to a breach of any
provision in this Agreement cannot operate or be construed as a waiver of any
subsequent breach by a party.

         12. SEVERABILITY. The invalidity or unenforceability of any particular
provision in this Agreement shall not affect the other provisions hereof, and
this Agreement shall be construed in all respects as if the invalid or
unenforceable provision were omitted.

         13. INTERPRETATION. The Company and Executive acknowledge and agree
that this Agreement has been reviewed and negotiated by each party and its or
his counsel, and the normal rule of construction, to the effect that ambiguities
are construed against the drafter, shall not be employed in the interpretation
of it. Executive acknowledges that Cooley Godward LLP has not represented
Executive in connection with the subject matter of this Agreement.

         14. ENTIRE AGREEMENT. Except as otherwise provided herein, this
Agreement (along with the Non-Compete Agreement) covers the entire understanding
of the parties as to the employment of Executive, superseding all prior
understandings and agreements, and no modification or amendment of its terms and
conditions shall be effective unless in writing and signed by the parties or
their respective duly authorized agents.

         15. GOVERNING LAW; JURY WAIVER. This Agreement shall be governed by
California law as applied to contracts entered into and performed entirely in
California by California residents. Executive hereby irrevocably waives any
right to a trial by jury in any action related to this Agreement, the
Non-compete Agreement or any action arising out of or related to his employment
with the Company.

         16. SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
inure to the benefit of the parties hereto and their successors, permitted
assigns, legal representatives and heirs. Executive may not assign his
obligations under this Agreement. Executive agrees that this Agreement may be
assigned by the Company upon a sale, transfer or reorganization of the Company,
and Executive shall perform all services required pursuant to this Agreement for
any such assignee company.

         17. GUARANTY BY VERTEX. Vertex acknowledges the foregoing and agrees
that Executive's acceptance of employment and Executive's other covenants
contained herein will

                                       7

<PAGE>

directly and indirectly benefit Vertex. In consideration for Executive's
acceptance of employment and Executive's other covenants contained herein,
Vertex, intending to be legally and equitably bound, hereby agrees in full to
each of the provisions of this Agreement and hereby agrees to guaranty and
guarantees performance in full of all terms and provisions of this Agreement by
the Company. This agreement and guaranty of Vertex shall be absolute and
unconditional, and without limiting the foregoing Vertex's obligations hereunder
shall not in any way be diminished, limited or otherwise affected by (i) the
liquidation or dissolution of the Company; (ii) any adverse change in the
condition (financial or otherwise) of the Company; or (3) the discharge or
release of the Company from its obligations hereunder for any reason, including,
without limitation, as a result of bankruptcy, receivership or similar
proceedings. Vertex agrees that you will not be required to take any action
against the Company as a condition to Vertex's liability and obligations under
this Section 16. The signature of its authorized representatives below shall be
confirmation of such agreement and guaranty by Vertex.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.

AURORA BIOSCIENCES CORPORATION

By: /s/ Stuart J.M. Collinson
    ------------------------------------------
Name: Stuart J.M. Collinson
      ----------------------------------------
Title: COB/CEO/PRES
       ---------------------------------------

/s/ Harry Stylli
------------------------------------
Harry Stylli

Agreed and accepted:

VERTEX PHARMACEUTICALS INCORPORATED

By: /s/ Joshua Boger
    ------------------------------------------
Name: Joshua Boger
      ----------------------------------------
Title: Chairman & CEO
       ---------------------------------------

Date: 29 April 2001
      ----------------------------------------

                                       8

<PAGE>

                                    EXHIBIT A

            NON-DISCLOSURE, NON-COMPETITION, AND INVENTIONS AGREEMENT

         1. NON-DISCLOSURE OF INFORMATION. I agree that, at all times during or
subsequent to my service as an employee or consultant, I will keep in strictest
trust and confidence all Confidential Information (as defined below) of Aurora
Biosciences Corporation and its parents, subsidiaries and affiliated companies
(together, "Aurora") that is disclosed to me or created by me or to which I have
access. I will not use or disclose such Confidential Information without the
written consent of Aurora, except as may be necessary in the ordinary course of
performing my duties as an employee or consultant of Aurora.

         2. SURRENDER OF CONFIDENTIAL INFORMATION. Upon termination of my
service as an employee or consultant, for whatever reason, I will promptly
surrender to Aurora all copies, in whatever form, of Aurora's Confidential
Information in my possession, custody or control, and I will not take with me
any of Aurora's Confidential Information that is embodied in a tangible medium
of expression.

         3. DISCLOSURE OF INVENTIONS. I will promptly and fully disclose to
Aurora (or any persons designated by it) all Inventions made, developed,
created, generated, conceived or reduced to practice by me, either alone or
jointly with others, whether during or after the period of my service as an
employee or consultant.

         4. ASSIGNMENT OF RIGHTS / EXCEPTION FOR NONASSIGNABLE INVENTIONS.

            4.1. ASSIGNMENT OF RIGHTS - I agree that all Confidential
Information and Inventions shall be the sole property of Aurora and its assigns,
and Aurora and its assigns shall be the sole owner of all patents, copyrights,
trademarks, trade secrets, and other rights and protection in connection
therewith. I hereby assign to Aurora any rights I may have or acquire in such
Confidential Information and Inventions. I further agree to assist Aurora in
every proper way (but at Aurora's expense) to obtain and from time to time
enforce patents, copyrights, trademarks, trade secrets, and other rights and
protection relating to said Confidential Information and Inventions in any and
all countries, and to that end I will execute all documents for use in applying
for, obtaining and enforcing such patents, copyrights, trademarks, trade secrets
and other rights and protection on such Confidential Information and Inventions,
as Aurora may reasonably request, together with any assignments thereof to
Aurora or persons designated by it. The foregoing obligation to assist Aurora
shall continue after the termination of my service as an employee or consultant,
but Aurora shall compensate me at a reasonable rate for time actually spent by
me on such assistance at Aurora's request after my termination.

            4.2 EXCEPTION OF NONASSIGNABLE INVENTIONS - This Agreement does not
apply to an Invention which qualifies fully as a nonassignable Invention under
Section 2870 of the California Labor Code (hereinafter "Section 2870"). I have
reviewed the notification of ATTACHMENT 1 (Limited Exclusion Notification) and
agree that my signature acknowledges receipt of the notification.

                                       9

<PAGE>

         5. NO CONFLICTING OBLIGATIONS. I represent and warrant to Aurora that I
have no interest or obligation, including without limitation any obligation to
keep in confidence any information acquired from previous employers or other
persons, which is inconsistent with or in conflict with this Agreement or which
would prevent, limit or impair my performance of any part of this Agreement or
the performance of my duties as an employee or consultant of Aurora. I agree to
notify Aurora immediately if any such interest or obligation arises.

         6. COVENANT NOT TO COMPETE. I acknowledge the unique nature of the
business of Aurora and the need of Aurora to maintain its competitive advantage
in its industry through the protection of its trade secrets and proprietary
information. Accordingly, I agree that during the term of my service as an
employee with Aurora and, in the event that my employment with Aurora shall
terminate for any reason less than eighteen months after the Commencement Date,
as that term is defined in that certain Employment Agreement between Aurora and
me of even date herewith, for one year following such termination of my
employment (the "Noncompete Period"), I will not:

(i) solicit or induce any person who is then a director, officer or employee of
Aurora to terminate his or her directorial or employment relationship with
Aurora (provided that the publication of "help wanted" or similar notices in
media of general circulation shall not be deemed to be a solicitation or
inducement for purposes of this clause); or

(ii) solicit or induce any party who is a customer or supplier of Aurora with
respect to the Business (defined below) to terminate or significantly diminish
its relationship with Aurora; or

(iii) market or sell any product or service that directly competes with any
product or service manufactured, sold or under development by Aurora in the
Business; or

(iv) research, develop or manufacture any product or service that directly
competes with any product or service manufactured, sold or under development by
Aurora in the Business.

         In order to assure that I do not breach any of the foregoing
provisions, I agree that during the Noncompete Period, I will not accept
employment with, advise, or provide consulting services to any department or
functional area of any business, which department or functional area primarily
engages in the Business, nor will I acquire any interest in (except an equity
interest of less than 5% of the total outstanding shares of a publicly traded
company) any business whose core business is substantially similar to the
Business, without first obtaining the written consent of Aurora. Aurora shall be
permitted to withhold such consent in its sole discretion unless my prospective
employer and I are able to provide Aurora with assurances reasonably
satisfactory to Aurora that I will not be assisting the prospective employer in
any of the prohibited activities listed above.

         7. DEFINITIONS.  For the purposes of this Agreement:

            7.1. "BUSINESS" means Aurora's business as of the date hereof of the
development and commercialization of cell-based assays and miniaturized
instrumentation the primary function of which is ultra-high throughput screening
using cell-based assays.

                                       10

<PAGE>

            7.2 "CONFIDENTIAL INFORMATION" includes any and all versions of any
of the following: (i) data or information concerning Aurora's business and
technologies; (ii) Aurora's proprietary pharmaceutical compounds, processes,
data and documentation; (iii) Aurora's proprietary computer software, firmware,
data, documentation and information; (iv) confidential, proprietary or trade
secret information received from or otherwise relating to Aurora's customers,
suppliers, consultants, collaborators or other third parties, including without
limitation the names of such persons or entities and the nature of Aurora's
relationships with them; (v) information concerning the employees of Aurora that
is considered confidential within Aurora; and (vi) any other information
(including information about Aurora's operations, personnel, products or
services) which, if misused or disclosed, could have a reasonable possibility of
materially and adversely affecting the business of Aurora (including, without
limitation, any such data, documentation and information created, developed,
produced, or made by me during the period of or arising out of my service as an
employee or consultant by Aurora); PROVIDED, HOWEVER, that "Confidential
Information" shall not include any information (a) which is now in the public
domain or which becomes part of the public domain by publication or otherwise,
except by your breach of this Agreement, (b) which is already in your possession
free of any obligation of confidence at the time it is communicated to you as
Confidential Information; (c) that is rightfully communicated to you free of any
obligation of confidence subsequent to the time it was communicated to you as
Confidential Information; (d) that is developed by you or others independently
of and without reference to any information communicated to you as Confidential
Information; or (e) that is communicated by Aurora or any of its employees,
consultants or other agents (other than you) to an unaffiliated third party free
of any obligation of confidence.

            7.3. "INVENTIONS" means all inventions, discoveries, developments,
designs, improvements, formulae, processes, techniques, computer programs,
strategies, specific know-how, data, and intellectual property, whether or not
patentable or registrable under patent, copyright or similar statutes (i) that
are made, developed, created, generated, conceived or reduced to practice by me,
either alone or jointly with others, while I am employed or retained as a
consultant by Aurora, or (ii) that result from tasks assigned to me by Aurora or
from the use of premises or property (including equipment, supplies, facilities
or Aurora's Confidential Information) owned, leased, or contracted for by Aurora
and that are made, developed, created, generated, conceived or reduced to
practice by me, either alone or jointly with others, whether during or after my
service as an employee or consultant with Aurora.

         8. ENFORCEMENT. I agree and acknowledge that the rights and obligations
set forth under this Agreement are of a unique and special nature and that
Aurora is, therefore, without an adequate legal remedy if I violate my
obligations under this Agreement. I agree, therefore, that the covenants made by
me under this Agreement shall be specifically enforceable in equity, in addition
to all other rights and remedies, at law or in equity or otherwise (including
termination of service as an employee or consultant) that may be available to
Aurora. If any provision of this Agreement shall, in whole or in part, prove to
be invalid for any reason, such invalidity shall affect only the portion of such
provision which shall be invalid, and in all other respects this Agreement shall
stand as if such invalid provisions, or the invalid portion thereof, had not
been a part hereof.

                                       11

<PAGE>

         9. GENERAL. This Agreement does not constitute a contract of employment
or to provide consulting services. It shall survive the termination of my
service as an employee or consultant. It may be modified only by an agreement in
writing signed by me and by an authorized representative of Aurora. This
Agreement shall be effective as of the date of commencement of my service as an
employee or consultant by Aurora, whichever is earlier. This Agreement shall be
governed by the laws of the State of California without giving effect to
conflict of laws provisions thereof. This Agreement shall be binding upon me and
my heirs and personal representatives and shall inure to the benefit of Aurora
and its successors, assigns and nominees.

AGREED AND ACCEPTED:

/s/ Harry Stylli
------------------------------------------
Harry Stylli

Date: April 29, 2001

AURORA BIOSCIENCES CORPORATION

By: /s/ Stuart J.M. Collinson
    --------------------------------------
Name: Stuart J.M. Collinson
      ------------------------------------
Title: COB/CEO/PRESIDENT
       -----------------------------------

Date: April 29, 2001

                                       12

<PAGE>

                                  ATTACHMENT 1

                         LIMITED EXCLUSION NOTIFICATION

         THIS IS TO NOTIFY you in accordance with Section 2870 of the California
Labor Code that the foregoing Agreement between you and Aurora Biosciences
Corporation ("Aurora") does not require you to assign or offer to assign to
Aurora any invention that you developed entirely on your own time without using
Aurora's equipment, supplies, facilities or trade secret information except for
those inventions that either:

         (1) Relate at the time of conception or reduction to practice of the
             invention to Aurora's business, or actual or demonstrably
             anticipated research or development of Aurora;

         (2) Result from any work performed by you for Aurora.

         To the extent a provision in the foregoing Agreement purports to
require you to assign an invention otherwise excluded from the preceding
paragraph, the provision is against the public policy of this state and is
unenforceable.

         This limited exclusion does not apply to any patent or invention
covered by a contract between Aurora and the United States or any of its
agencies requiring full title to such patent or invention to be in the United
States.

         I ACKNOWLEDGE RECEIPT of a copy of this notification.

                                          By: /s/ Harry Stylli
                                             ---------------------------------
                                              Harry Stylli

                                          Date: April 29, 2001
                                               -------------------------------

WITNESSED BY:

/s/ Stuart J.M. Collinson
-------------------------------
Signature

Stuart J.M. Collinson
-------------------------------
(Printed Name of Representative)

  4-29-01
-------------------------------
Date

                                       13

<PAGE>

                                    EXHIBIT B

                                   MILESTONES

       1. Organize meeting within BD group to discuss integration-related issues

       2. Establish an integration plan for the BD group

       3. Visit Vertex and meet with Vertex representatives to discuss
       integration of each company's BD groups

       4. Ensure that a member of the BD group notifies key commercial partners
       and collaborators of the merger<PAGE>

                       MORGAN STANLEY SELECT EQUITY TRUST
                   SELECT S & P INDUSTRIAL PORTFOLIO 2001-2
                            REFERENCE TRUST AGREEMENT

          This Reference Trust Agreement dated         , 2001 between MORGAN
STANLEY DW INC., as Depositor, and The Chase Manhattan Bank, as Trustee, sets
forth certain provisions in full and incorporates other provisions by reference
to the document entitled "Sears Equity Investment Trust, Trust Indenture and
Agreement" dated January 22, 1991, as amended on March 16, 1993, July 18, 1995
and December 30, 1997 (the "Basic Agreement"). Such provisions as are
incorporated by reference constitute a single instrument (the "Indenture").

                                WITNESSETH THAT:

          In consideration of the premises and of the mutual agreements herein
contained, the Depositor and the Trustee agree as follows:

                                       I.

                     STANDARD TERMS AND CONDITIONS OF TRUST

          Subject to the provisions of Part II hereof, all the provisions
contained in the Basic Agreement are herein incorporated by reference in their
entirety and shall be deemed to be a part of this instrument as fully and to the
same extent as though said provisions had been set forth in full in this
instrument except that the Basic Agreement is hereby amended in the following
manner:

          A.   Article I, Section 1.01, paragraph (29) defining "Trustee" shall
     be amended as follows:

     "'Trustee' shall mean The Chase Manhattan Bank, or any successor trustee
          appointed as hereinafter provided."

          B.   Reference to United States Trust Company of New York in its
     capacity as Trustee is replaced by The Chase Manhattan Bank throughout the
     Basic Agreement.

<PAGE>
                                      -2-

          C.   Reference to "Morgan Stanley Dean Witter Select Equity Trust" is
     replaced by "Morgan Stanley Select Equity Trust".

          D.   Section 3.01 is amended to substitute the following:

               SECTION 3.01. INITIAL COST The costs of organizing the Trust and
          sale of the Trust Units shall, to the extent of the expenses
          reimbursable to the Depositor provided below, be borne by the Unit
          Holders, PROVIDED, HOWEVER, that, to the extent all of such costs are
          not borne by Unit Holders, the amount of such costs not borne by Unit
          Holders shall be borne by the Depositor and, PROVIDED FURTHER,
          HOWEVER, that the liability on the part of the Depositor under this
          section shall not include any fees or other expenses incurred in
          connection with the administration of the Trust subsequent to the
          deposit referred to in Section 2.01. Upon notification from the
          Depositor that the primary offering period is concluded, the Trustee
          shall withdraw from the Account or Accounts specified in the
          Prospectus or, if no Account is therein specified, from the Principal
          Account, and pay to the Depositor the Depositor's reimbursable
          expenses of organizing the Trust and sale of the Trust Units in an
          amount certified to the Trustee by the Depositor. If the balance of
          the Principal Account is insufficient to make such withdrawal, the
          Trustee shall, as directed by the Depositor, sell Securities
          identified by the Depositor, or distribute to the Depositor Securities
          having a value, as determined under Section 4.01 as of the date of
          distribution, sufficient for such reimbursement. The reimbursement
          provided for in this section shall be for the account of the
          Unitholders of record at the conclusion of the primary offering period
          and shall not be reflected in the computation of the Unit Value prior
          thereto. As used herein, the Depositor's reimbursable expenses of
          organizing the Trust and sale of the Trust Units shall include the
          cost of the initial preparation and typesetting of the registration
          statement, prospectuses (including preliminary prospectuses), the
          indenture, and other documents relating to the Trust, SEC and state
          blue sky registration fees, the cost of the ini-

<PAGE>
                                      -3-

          tial valuation of the portfolio and audit of the Trust, the initial
          fees and expenses of the Trustee, and legal and other out-of-pocket
          expenses related thereto, but not including the expenses incurred in
          the printing of preliminary prospectuses and prospectuses, expenses
          incurred in the preparation and printing of brochures and other
          advertising materials and any other selling expenses. Any cash which
          the Depositor has identified as to be used for reimbursement of
          expenses pursuant to this Section shall be reserved by the Trustee for
          such purpose and shall not be subject to distribution or, unless the
          Depositor otherwise directs, used for payment of redemptions in excess
          of the per-Unit amount allocable to Units tendered for redemption.

          E.   Reference to "Dean Witter Reynolds Inc." is replaced by "Morgan
     Stanley DW Inc."

          F.   Section 2.03 is amended to add the following to the end of the
     first paragraph thereof. The number of Units may be increased through a
     split of the Units or decreased through a reverse split thereof, as
     directed by the Depositor, which revised number of Units shall be recorded
     by Trustee on its books.

                                       II.

                      SPECIAL TERMS AND CONDITIONS OF TRUST

          The following special terms and conditions are hereby agreed to:

          A.   The Trust is denominated Morgan Stanley Select Equity Trust
     Select S & P Industrial Portfolio 2001-2 (the "S & P Industrial Trust").

          B.   The publicly traded stocks listed in Schedule A hereto are those
     which, subject to the terms of this Indenture, have been or are to be
     deposited in trust under this Indenture.

<PAGE>
                                      -4-

          C.   The term, "Depositor" shall mean Morgan Stanley DW Inc.

          D.   The aggregate number of Units referred to in Sections 2.03 and
     9.01 of the Basic Agreement is        for the S & P Industrial Trust.

          E.   A Unit is hereby declared initially equal to 1/      th for the
     Strategic Growth Trust.

          F.   The term "In-Kind Distribution Date" shall mean       , 2002.

          G.   The term "Record Dates" shall mean          , 2002,         ,
     2002,        , 2002 and such other date as the Depositor may direct.

          H.   The term "Distribution Dates" shall mean      , 2002,       ,
     2002,        , 2002 and such other date as the Depositor may direct.

          I.   The term "Termination Date" shall mean        , 2002.

          J.   The Depositor's Annual Portfolio Supervision Fee shall be a
     maximum of $     per 100 Units.

          K.   The Trustee's annual fee as defined in Section 6.04 of the
     Indenture shall be $     per 100 Units if the greatest number of Units
     outstanding during the period is 10,000,000 or more; $     per 100 Units if
     the greatest number of Units outstanding during the period is between
     5,000,000 and 9,999,999; and $      per 100 Units if the greatest number of
     Units outstanding during the period is 4,999,999 or less.

          L.   For a Unit Holder to receive an "in--kind" distribution during
     the life of the Trust, such Unit Holder must tender at least 25,000 Units
     for redemption. There is no minimum amount of Units that a Unit Holder must
     tender in order to receive an "in-kind" distribution on the In-Kind Date or
     in connection with a rollover.

          M.   Paragraph (b)(ii) of Section 9.03 is amended to provide that the
     period during which the Trustee shall liquidate the Trust Securities shall
     not exceed 14 business days commencing on the first business day following
     the In-Kind Date.

<PAGE>
                                      -5-

                  (Signatures and acknowledgments on separate pages)

<PAGE>
                                      -6-

          The Schedule of Portfolio Securities in the prospectus included in
this Registration Statement is hereby incorporated by reference herein as
Schedule A hereto.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}]]